Close Menu

NEW YORK – ERS Genomics, a vessel for intellectual property held by CRISPR pioneer Emmanuelle Charpentier, announced Tuesday a licensing deal with Applied StemCell.

Under the agreement, Milpitas, California-based Applied StemCell will commercialize CRISPR gene editing services and reagents.

"Applied StemCell has been a leading stem cell company … for many years," ERS Genomics CEO Eric Rhodes said in a statement. "It is exciting to see their expertise in cell and animal models being combined with the power of CRISPR gene editing."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.